A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.

Trial Details

NCT ID
NCT07079228
Phase
PHASE3
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • QLS31905
  • Nab-paclitaxel.
  • Gemcitabine
  • Placebo for QLS31905
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Subjects voluntarily participate in the study and sign the informed consent form;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  • Expected survival time ≥ 3 months;
  • Histologically or cytologically confirmed diagnosis of pancreatic cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →